Arrivo targets major depressive disorder in females after early efficacy data
Arrivo BioVentures’ SIRT6 activator SP-624 has been found to significantly reduce symptoms of major depressive disorder (MDD), but only in…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly…
-
A slow start for self-amplifying mRNA vaccines
A year after bursting onto the scene amid the RNA renaissance, scientific challenges and regulatory resistance have held back self-amplifying…
-
Editas and Genevant team up to develop gene editing therapies
Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR and LNP technologies under…
-
bit.bio defends European patent for ‘novel’ opti-ox technology
bit.bio has successfully defended the European patent for its opti-ox cell programming technology. After a hearing held on 25 September…
-
Hanmi and MEDiC ink cancer biomarker collaboration deal
Leading Korean biopharma, Hanmi Pharmaceutical, has entered into a research collaboration and financing agreement with Silicon Valley startup MEDiC Life…
-
Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’
Anima Biotech is utilising machine learning (ML) to investigate the role of messenger RNA (mRNA) in disease, revealing previously unseen…
-
Amgen and MediLink to collaborate on SCLC combination therapy
Amgen and MediLink Therapeutics have agreed to a research and supply collaboration to develop a combination therapy for extensive-stage small…
-
A rational design approach to RNA targeting could replace large-scale screening
As interest mounts in using RNA as a therapeutic target, a group at the Institute of Chemistry in Nice is…
-
LoQus23 secures $43m to advance Huntington’s Disease therapy
LoQus23 closed a round of Series A financing to advance development of its lead candidate for Huntington’s Disease. The Cambridge,…